Published in Cancer Res on January 01, 2000
Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med (2002) 1.88
Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest (2003) 1.71
Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr Opin Immunol (2000) 1.56
Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit Rev Immunol (2000) 1.47
Cancer vaccines: progress reveals new complexities. J Clin Invest (2002) 1.29
The promise of nucleic acid vaccines. Gene Ther (2000) 1.05
Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine (2004) 1.02
Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J Virol (2005) 1.00
Type I Interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine (2006) 0.99
Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS One (2012) 0.96
Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J Virol (2001) 0.96
Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infect Immun (2003) 0.95
Vaccination with a Sindbis virus-based DNA vaccine expressing antigen 85B induces protective immunity against Mycobacterium tuberculosis. Infect Immun (2005) 0.92
Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus. J Virol (2005) 0.90
Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine. J Virol (2007) 0.88
Role of TLR3 in the immunogenicity of replicon plasmid-based vaccines. Gene Ther (2008) 0.88
Vaccines to die for. Nat Biotechnol (2001) 0.87
DNA vaccines and apoptosis: to kill or not to kill? J Clin Invest (2003) 0.85
Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation. J Virol (2012) 0.85
Alphavirus-based vaccines. Viruses (2014) 0.84
Enhancement of DNA tumor vaccine efficacy by gene gun-mediated codelivery of threshold amounts of plasmid-encoded helper antigen. Blood (2008) 0.82
Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines. Virol J (2011) 0.80
Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity. Mol Ther (2013) 0.79
The extent of the uptake of plasmid into the skin determines the immune responses induced by a DNA vaccine applied topically onto the skin. J Pharm Pharmacol (2011) 0.79
A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. Ther Adv Vaccines (2014) 0.79
Alphaviruses in gene therapy. Viruses (2015) 0.79
Modulation of plasmid DNA vaccine antigen clearance by caspase 12 RNA interference potentiates vaccination. Clin Vaccine Immunol (2011) 0.79
New applications of alphavirus-based expression vectors. Cytotechnology (2001) 0.75
Replicon RNA Viral Vectors as Vaccines. Vaccines (Basel) (2016) 0.75
[Genetic immunization: new ways for protective and therapeutic vaccines against allergic diseases]. Wien Med Wochenschr (2007) 0.75
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 9.77
Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med (1998) 5.59
DNA vaccines. Annu Rev Immunol (1997) 5.05
A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc Natl Acad Sci U S A (1997) 3.88
Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med (1999) 3.64
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol (1995) 2.45
Enhancing immune responses using suicidal DNA vaccines. Nat Biotechnol (1998) 2.20
Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol (1996) 2.15
Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci U S A (1997) 2.11
Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J Virol (1996) 2.01
Exposing the immunology of naked DNA vaccines. Immunity (1995) 1.80
Cancer therapy using a self-replicating RNA vaccine. Nat Med (1999) 1.76
DNA and RNA-based vaccines: principles, progress and prospects. Vaccine (1999) 1.76
Sindbis virus induces apoptosis through a caspase-dependent, CrmA-sensitive pathway. J Virol (1998) 1.71
Type I interferons are essential mediators of apoptotic death in virally infected cells. Genes Cells (1998) 1.59
DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol (1998) 1.57
Activation of the IFN-inducible enzyme RNase L causes apoptosis of animal cells. Virology (1997) 1.35
Alphavirus vectors for gene expression and vaccines. Curr Opin Biotechnol (1999) 1.34
CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J Immunol (1998) 1.32
Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. Cancer Res (1994) 1.01
The Semliki Forest virus vector induces p53-independent apoptosis. J Gen Virol (1998) 0.92
Tumor vaccines--a reality at last? J Immunother (1998) 0.89
Plasmid DNA-based alphavirus expression vectors for nucleic acid immunization. IDrugs (1998) 0.83
Cancer vaccines: novel approaches and new promise. Pharmacol Ther (1999) 0.82
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03
PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature (1993) 8.83
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood (2000) 4.78
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A (1999) 3.66
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol (1998) 3.03
Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol (1999) 2.94
Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med (1998) 2.84
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am (1997) 2.71
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol (1995) 2.45
Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat Med (2005) 2.28
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst (1998) 2.17
Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol (1996) 2.15
Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci U S A (1997) 2.11
Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res (2001) 2.11
IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol (1995) 2.02
Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J Virol (1996) 2.01
Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther (2008) 1.94
Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst (1995) 1.90
Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med (2000) 1.90
B16 as a mouse model for human melanoma. Curr Protoc Immunol (2001) 1.80
Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol (1991) 1.77
Cancer therapy using a self-replicating RNA vaccine. Nat Med (1999) 1.76
DNA and RNA-based vaccines: principles, progress and prospects. Vaccine (1999) 1.76
The primary site of replication alters the eventual site of persistent infection by polyomavirus in mice. J Virol (1984) 1.73
Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol (1999) 1.71
HLA associations in the antitumor response against malignant melanoma. J Immunother Emphasis Tumor Immunol (1995) 1.71
Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol (2000) 1.66
Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods (1997) 1.63
Replicon vectors derived from Sindbis virus and Semliki forest virus that establish persistent replication in host cells. J Virol (2000) 1.58
DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol (1998) 1.57
Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res (1999) 1.55
Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J Virol (2000) 1.52
Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol (2000) 1.52
The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J Sci Am (2000) 1.52
Detection of DNA and RNA virus genomes in organ systems of whole mice: patterns of mouse organ infection by polyomavirus. J Virol (1984) 1.50
IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol (1996) 1.49
Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res (1994) 1.48
Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol (2000) 1.47
Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit Rev Immunol (2000) 1.47
Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother (1997) 1.47
Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. J Clin Invest (1999) 1.46
Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res (1995) 1.45
Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol (1996) 1.44
Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol (1996) 1.43
Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. J Immunol (1993) 1.39
Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. Proc Natl Acad Sci U S A (1999) 1.38
Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst (1997) 1.36
Alphavirus vectors for gene expression and vaccines. Curr Opin Biotechnol (1999) 1.34
Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine (1997) 1.32
CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J Immunol (1998) 1.32
Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma. Cold Spring Harb Symp Quant Biol (2009) 1.29
VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol Ther (2000) 1.28
PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway. Oncogene (2006) 1.28
Safe surgery of lesions near the motor cortex using intra-operative mapping techniques: a report on 50 patients. Acta Neurochir (Wien) (1992) 1.27
Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J Immunol (1999) 1.26
Direct transfection of viral and plasmid DNA into the liver or spleen of mice. Proc Natl Acad Sci U S A (1984) 1.22
T-cell recognition of human melanoma antigens. J Immunother Emphasis Tumor Immunol (1993) 1.22
Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors. Neuroreport (2000) 1.20
An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci U S A (2000) 1.17
Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. J Immunother Emphasis Tumor Immunol (1994) 1.16
Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. Proc Natl Acad Sci U S A (1997) 1.15
Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res (2000) 1.12
Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens. Cancer Res (1999) 1.10
Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res (2000) 1.08
The antiviral enzymes PKR and RNase L suppress gene expression from viral and non-viral based vectors. Nucleic Acids Res (1999) 1.07
Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. J Immunol (1995) 1.07
Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int J Cancer (1999) 1.07
Immunization against endogenous retroviral tumor-associated antigens. Cancer Res (2001) 1.05
The promise of nucleic acid vaccines. Gene Ther (2000) 1.05
Distinct dysregulation of lipid metabolism by unliganded thyroid hormone receptor isoforms. Mol Endocrinol (2009) 1.04
The effects of euglycemic hyperinsulinemia and amino acid infusion on regional and whole body glucose disposal in man. Metabolism (1991) 1.04
The phylogenetic relationship and complete nucleotide sequence of human papillomavirus type 35. Virology (1992) 1.03
Alphavirus DNA and particle replicons for vaccines and gene therapy. Dev Biol (Basel) (2000) 1.01
Countering the 'counterattack' hypothesis. Nat Med (2001) 1.01
Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res (1996) 1.00
Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen. J Immunother Emphasis Tumor Immunol (1995) 0.99
Evaluation of pyrimidine PNA binding to ssDNA targets from nonequilibrium melting experiments. Nucleic Acids Res (1997) 0.97
T cell-tumor cell: a fatal interaction? Cancer Immunol Immunother (1998) 0.97
Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization. J Immunol Methods (1998) 0.95
Characteristics of reactive electropermeable points on the auricles of coronary heart disease patients. Clin Cardiol (1993) 0.92
Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Ther (2012) 0.91
Zinc-induced neuronal death in cortical neurons. Cell Mol Biol (Noisy-le-grand) (2000) 0.91
Features of cap polyposis by magnifying colonoscopy. Gastrointest Endosc (2000) 0.90
Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. Cancer Res (1995) 0.90
Route of immunization and the therapeutic impact of recombinant anticancer vaccines. J Natl Cancer Inst (1997) 0.89
The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent. J Virol (1999) 0.89
Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. J Immunother (1999) 0.89
Necrotizing arterial lesions in mice-bearing tumors induced by polyoma virus. J Exp Pathol (1987) 0.89
Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor. J Immunol (1993) 0.89
ARF promotes accumulation of retinoblastoma protein through inhibition of MDM2. Oncogene (2007) 0.87